Related Experiment Video
Updated: Jun 26, 2026
Establishment of a Clinic-based Biorepository
Published on: May 29, 2017
Expression of SART-1 mRNA in canine squamous cell carcinomas
Yumi Takaishi1, Yukari Yoshida, Kazuhide Nakagaki
1College of Veterinary Medicine, Nippon Jui-Seimeikagaku University, Japan.
Abstract:
SART-1, a squamous cell carcinoma (SCC) antigen recognized by cytotoxic T lymphocytes, has been useful in human cancer therapy. The SART-1(259) peptide is a potential candidate for vaccine. The present study examined an orthologue of the mRNA coding this peptide in canine SCCs. Specimens were obtained from seven canine patients with SCC, and the mRNA was isolated from the samples. The SART-1 and beta-actin genes were amplified by reverse-transcription polymerase chain reaction, using the isolated mRNA as a template. Canine SART-1 was amplified in six of the seven specimens, while beta-actin was detected in all the samples. In dogs, carcinomas expressing SART-1 could be a target for cytotoxic T lymphocyte mediated immunotherapy.
Insights
Researchers investigated canine squamous cell carcinoma (SCC) antigen SART-1, a target for cancer therapy. Canine SART-1 mRNA was detected in most SCC samples, suggesting its potential for immunotherapy in dogs.
Area of Science:
- Immunology
- Veterinary Oncology
- Molecular Biology
Background:
- Squamous cell carcinoma (SCC) antigen 1 (SART-1) is recognized by cytotoxic T lymphocytes and has therapeutic applications in human cancer.
- The SART-1(259) peptide is a candidate for cancer vaccines.
- Investigating SART-1 orthologues in canine SCC is crucial for potential veterinary immunotherapy.
Purpose of the Study:
- To examine the presence and expression of a SART-1 orthologue in canine squamous cell carcinoma (SCC).
- To evaluate the potential of canine SART-1 as a target for cytotoxic T lymphocyte-mediated immunotherapy in dogs.
Main Methods:
- mRNA was isolated from seven canine SCC specimens.
- Reverse-transcription polymerase chain reaction (RT-PCR) was used to amplify SART-1 and beta-actin genes.
- Gene amplification was performed using isolated mRNA as a template.
Main Results:
- Canine SART-1 mRNA was successfully amplified in six out of seven SCC specimens.
- The beta-actin gene, used as a control, was detected in all samples.
- These findings indicate SART-1 expression in a majority of canine SCCs.
Conclusions:
- Carcinomas expressing SART-1 in dogs can be identified as potential targets for immunotherapy.
- Cytotoxic T lymphocyte-mediated immunotherapy targeting SART-1 shows promise for canine cancer treatment.
- Further research into SART-1 based vaccines could advance veterinary oncology.
